Newsome SD, et al. A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis. Abstract 60. ECTRIMS 11-13 sept 2019, Stockholm, Zweden.
Bootcamp voor training in acute neurologie
mei 2024 | Dementie, Epilepsie, Hoofdpijn, Neuro-musculair, Neuro-vasculair